Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165464 · ClinicalTrials.gov registry record · Phase 2
Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer
A Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT00165464: Completed Phase 2 study of Gastric Cancer and Esophageal Cancer, sponsored by Dana-Farber Cancer Institute.
NCT00165464 is a Phase 2 study of Gastric Cancer and Esophageal Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 54 participants, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165464, a Phase 2 study of Gastric Cancer and Esophageal Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Irinotecan
- DRUG Taxotere
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
- Faulkner Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-08 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00165464 record still lists
NCT00165464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 319-participant average among 153 other Gastric Cancer trials with a reported enrollment target (83% lower).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT00165464 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00165464 about?
NCT00165464 is a clinical study titled "Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer". This is a phase II study of taxotere, cisplatin and irinotecan (CPT-11) used in combination to treat metastatic esophageal and gastric cancer in an effort to see what effects (good and bad) the combination may have on the patients cancer.
What is the current status of trial NCT00165464?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-08. Estimated completion is 2009-04.
What conditions does trial NCT00165464 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, GE Junction Cancer.
What interventions are being tested in trial NCT00165464?
The interventions under investigation include: Cisplatin (DRUG), Irinotecan (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00165464?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00165464 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00165464's enrollment target sits among peer trials
54 116th of 153 higher than 37 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia